Pemphigus Gestationis
Pemphigus gestationis (PG) is characterized by the formation of tense blisters and erythematous plaques on the abdomen, often accompanied by severe pruritus. At our company, we are dedicated to the development of innovative drugs and therapies for autoimmune diseases and inflammation, including pemphigus gestationis.
Overview of Pemphigus Gestationis
Pemphigus gestationis, also known as gestational pemphigoid, is an autoimmune bullous disorder that primarily affects pregnant women. The most commonly targeted antigen in PG is BP180 (also known as collagen XVII), which plays a crucial role in maintaining the integrity of the dermal-epidermal junction. Autoantibodies binding to BP180 lead to the activation of complement and subsequent recruitment of inflammatory cells, resulting in blister formation. Another important antigen implicated in PG is BP230, a cytoplasmic protein associated with desmosomes. Autoantibodies against BP230 can also contribute to the pathogenesis of PG by disrupting desmosomal adhesion, further compromising the integrity of the skin.
Fig.1 Representative case of histopathological analysis of pemphigus gestationis. (Fernanda L. G. A., et al., 2020)
Drug Discovery and Development for Pemphigus Gestationis
In the quest for more targeted and effective therapeutics, innovative biological therapies have shown promise in the therapeutics of PG. A monoclonal antibody targeting the alpha subunit of the interleukin 4 receptor, has demonstrated rapid remission of symptoms and the ability to reduce dependence on high-dose systemic steroids. This therapy holds particular potential for women with co-morbidities, where systemic steroid therapy may be contraindicated.
We are proud to lead the way in providing groundbreaking advancements in the field of therapeutics for pemphigus gestationis. To gain comprehensive insights into the range of therapy services we offer, we invite you to explore the links provided below.
Small Molecule Drug
Probiotics Therapy
Therapeutic Antibody
Cell Therapy
Gene Therapy
Therapeutics Development
Our Services
At our company, we are committed to advancing the field of autoimmune disease research and offering comprehensive services for pemphigus gestationis diagnostics and therapy development. To facilitate preclinical research and accelerate the development of potential therapies, we specialize in the development of pemphigus gestationis animal models and in vitro models. Our expertise in model development ensures reliable and reproducible results, enabling efficient screening of therapeutic candidates
Transgenic Models
One example of a transgenic mouse model for PG is the BP180 knockout mouse. These mice lack the expression of the BP180 protein, which is a major target antigen in PG. By studying these mice, we can gain insights into the role of BP180 in disease development, the immune response, and potential therapeutic targets.
Induced Animal Models
In the case of pemphigus gestationis, we may utilize various methods to induce a similar autoimmune response observed in human patients. This can include the administration of specific antibodies, such as autoantibodies against BP230, or the use of adjuvants to trigger an immune response.
By studying primary keratinocyte cultures, we can assess the effects of various factors, such as autoantibodies or inflammatory mediators, on keratinocyte behavior and the subsequent blister formation.
Our company provides specialized and customized organoid model development services for pemphigus gestationis, such as skin and placental organoids, for the evaluation of potential therapeutics.
From pharmacokinetic and pharmacodynamic assessments to toxicity studies and dose optimization, we provide comprehensive preclinical support. In addition to the aforementioned range of services and models, we also specialize in tailoring customized solutions and developing disease models that precisely align with your distinctive requirements. Should our array of services capture your interest, we warmly encourage you to reach out to us without hesitation.
Reference
- Fernanda L. G. A., et al. "Pemphigoid Gestationis: A Third-Trimester Multigravida with a Severe Disease." J Dermatol Res Ther 6 (2020): 086.